Targeting histone K4 trimethylation for treatment of cognitive and synaptic deficits in mouse models of Alzheimer’s disease
Open accessThe DOI matches its Crossref record; 73 of the 73 references it cites were found in a registry or an index.
Abstract
This study has found a novel epigenetic mechanism and a potential therapeutic strategy for AD and related diseases.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures







Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“and inhibiting H3K4-specific methyltransferases, including MLL1-4 (also named as KMT2A-D) and SETD1a/b, leads to the substantial recovery of glutamatergic synaptic function in PFC pyramidal neurons, and the significant improvement of memory-related behaviors in mutant Tau transgenic mice 260.”
From Mechanisms of synaptic transmission dysregulation in the prefrontal cortex: pathophysiological implications (2022) · cites this paper as [260]
The cited source says what the claim attributes to it.
In the citing paper
“Indeed, the selective SGK1 inhibitor GSK650394 decreases Tau hyperphosphorylation, restores synaptic transmission, and ameliorate memory deficits in P301S mice [10].”
From Elevated SGK1 increases Tau phosphorylation and microtubule instability in Alzheimer’s patient-derived cortical neurons (2026) · cites this paper as [10]
The cited source says what the claim attributes to it.
In the citing paper
“RNA sequencing (RNAseq) of the prefrontal cortex (PFC) of the P301S human Tau transgenic mouse model of dementia has identified Serum and Glucocorticoid-regulated Kinase-1 (Sgk1) as one of the top-ranking upregulated genes [10].”
From Elevated SGK1 increases Tau phosphorylation and microtubule instability in Alzheimer’s patient-derived cortical neurons (2026) · cites this paper as [10]
The cited source says what the claim attributes to it.
In the citing paper
“SGK1 inhibition lowers pTau and rescues the deficits in synaptic transmission and memory tests in P301S mice [10].”
From Elevated SGK1 increases Tau phosphorylation and microtubule instability in Alzheimer’s patient-derived cortical neurons (2026) · cites this paper as [10]
The cited source says what the claim attributes to it.
In the citing paper
“Indeed, the selective SGK1 inhibitor GSK650394 decreases Tau hyperphosphorylation, restores synaptic transmission, and ameliorate memory deficits in P301S mice [10].”
From Elevated SGK1 increases Tau phosphorylation and microtubule instability in Alzheimer’s patient-derived cortical neurons (2026) · cites this paper as [10]
3 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources
Huang, D. W., Sherman, B. T., & Lempicki, R. A. (2009) · Nature Protocols · doi:10.1038/nprot.2008.211 · Cited by 35,890
Soluble protein oligomers in neurodegeneration: lessons from the Alzheimer's amyloid β-peptide
Haass, C., & Selkoe, D. J. (2007) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm2101 · Cited by 4,744
Shankar, G. M., Li, S., Mehta, T. H., Garcia-Munoz, A., Shepardson, N. E., Smith, I., Brett, F. M., Farrell, M. A., Rowan, M. J., Lemere, C. A., et al. (2008) · Nature Medicine · doi:10.1038/nm1782 · Cited by 3,685
Oakley, H., Cole, S. L., Logan, S., Maus, E., Shao, P., Craft, J., Guillozet-Bongaarts, A., Ohno, M., Disterhoft, J., Van Eldik, L., et al. (2006) · The Journal of Neuroscience · doi:10.1523/jneurosci.1202-06.2006 · Cited by 3,530 · cited 3×
“The transgenic mice carrying five familial AD mutations on human amyloid precursor protein (K670N/M671L + I716V + V717I) and human presenilin 1 (M146L + L286V), 5xFAD (27), were a gift from W. E. Van Nostrand (Stony Brook University).”
BackgroundInfluentialAdvancing research diagnostic criteria for Alzheimer's disease: the IWG-2 criteria
Dubois, B., Feldman, H. H., Jacova, C., Hampel, H., Molinuevo, J. L., Blennow, K., DeKosky, S. T., Gauthier, S., Selkoe, D., Bateman, R., et al. (2014) · The Lancet Neurology · doi:10.1016/s1474-4422(14)70090-0 · Cited by 3,321
Cellular basis of working memory
Goldman-Rakic, P. S. (1995) · Neuron · doi:10.1016/0896-6273(95)90304-6 · Cited by 2,663
The contribution of de novo coding mutations to autism spectrum disorder
Iossifov, I., O’Roak, B. J., Sanders, S. J., Ronemus, M., Krumm, N., Levy, D., Stessman, H. A., Witherspoon, K. T., Vives, L., Patterson, K. E., et al. (2014) · Nature · doi:10.1038/nature13908 · Cited by 2,585
Self-citationSingle-cell transcriptomic analysis of Alzheimer’s disease
Mathys, H., Davila-Velderrain, J., Peng, Z., Gao, F., Mohammadi, S., Young, J. Z., Menon, M., He, L., Abdurrob, F., Jiang, X., et al. (2019) · Nature · doi:10.1038/s41586-019-1195-2 · Cited by 2,568
Synapse Loss and Microglial Activation Precede Tangles in a P301S Tauopathy Mouse Model
Yoshiyama, Y., Higuchi, M., Zhang, B., Huang, S.-M., Iwata, N., Saido, T. C., Maeda, J., Suhara, T., Trojanowski, J. Q., & Lee, V. M.-Y. (2007) · Neuron · doi:10.1016/j.neuron.2007.01.010 · Cited by 2,208
Tau-mediated neurodegeneration in Alzheimer’s disease and related disorders
Ballatore, C., Lee, V. M.-Y., & Trojanowski, J. Q. (2007) · Nature Reviews Neuroscience · doi:10.1038/nrn2194 · Cited by 2,174
Cited by
Epigenetic regulation of aging: implications for interventions of aging and diseases
Wang, K., Liu, H., Hu, Q., Wang, L., Liu, J., Zheng, Z., Zhang, W., Ren, J., Zhu, F., & Liu, G.-H. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-01211-8 · Cited by 663
“In a mouse model of Alzheimer’s disease (AD), the level of H3K4me3 and its catalyzing enzymes increases in the prefrontal cortex, a crucial brain region impaired in AD, and treating these mice with an inhibitor of H3K4 HMTs promotes the recovery of prefrontal cortex functions.(66) The H3K4me3 level has also been shown…”
BackgroundAging Biomarker Consortium, Bao, H., Cao, J., Chen, M., Chen, M., Chen, W., Chen, X., Chen, Y., Chen, Y., Chen, Y., et al. (2023) · Science China Life Sciences · doi:10.1007/s11427-023-2305-0 · Cited by 376
The role of histone modifications: from neurodevelopment to neurodiseases
Park, J., Lee, K., Kim, K., & Yi, S.-J. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-01078-9 · Cited by 297
“Administration of a specific Sgk1 inhibitor reduces a hyperphosphorylated tau protein, restores glutamatergic synaptic function, and ameliorates memory deficits in AD mice.(187) H3K9me2 is associated with transcriptional repression.”
BackgroundYan, Z., & Rein, B. (2022) · Molecular Psychiatry · doi:10.1038/s41380-021-01092-3 · Cited by 300
“On the other hand, the elevation of permissive histone mark H3K4me3 in AD leads to the upregulation of genes involved in cell stress, such as serum- and glucocorticoid-inducible kinase 1 (SGK1), resulting in hyperphosphorylation of tau, disintegration of microtubules, and disruption of vital protein transport [260].”
BackgroundSelf-citationMethylation across the central dogma in health and diseases: new therapeutic strategies
Liu, R., Zhao, E., Yu, H., Yuan, C., Abbas, M. N., & Cui, H. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01528-y · Cited by 165
Epigenetic Mechanisms in Memory and Cognitive Decline Associated with Aging and Alzheimer’s Disease
Maity, S., Farrell, K., Navabpour, S., Narayanan, S. N., & Jarome, T. J. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms222212280 · Cited by 134
Genomic Instability and Epigenetic Changes during Aging
López-Gil, L., Pascual-Ahuir, A., & Proft, M. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241814279 · Cited by 104
Histone Modifications in Alzheimer’s Disease
Santana, D. A., Smith, M. D. A. C., & Chen, E. (2023) · Genes · doi:10.3390/genes14020347 · Cited by 118
“H3K4me3 ↑ Human brain Mouse models [102,103]”
BackgroundHistone Methylation Regulation in Neurodegenerative Disorders
Basavarajappa, B. S., & Subbanna, S. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22094654 · Cited by 105
“Similarly, the H3K4m3 mark, as well as specific HMTs, such as KMT2A-D in the PFC nuclear fraction from human AD, was significantly enhanced without affecting H3K27me3 or H3K4me marks [104].”
BackgroundRole of Histone Post-Translational Modifications in Inflammatory Diseases
Lin, Y., Qiu, T., Wei, G., Que, Y., Wang, W., Kong, Y., Xie, T., & Chen, X. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.852272 · Cited by 112
Self-citationPrasanth, M. I., Sivamaruthi, B. S., Cheong, C. S. Y., Verma, K., Tencomnao, T., Brimson, J. M., & Prasansuklab, A. (2024) · Antioxidants · doi:10.3390/antiox13050606 · Cited by 71
“Further, inhibiting specified methyltransferases using inhibitors in AD mice restored synaptic functions and improved memory [94].”
BackgroundRole of Receptors in Relation to Plaques and Tangles in Alzheimer’s Disease Pathology
Sharma, K., Pradhan, S., Duffy, L. K., Yeasmin, S., Bhattarai, N., & Schulte, M. K. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms222312987 · Cited by 60
Omics-based biomarkers discovery for Alzheimer's disease
Aerqin, Q., Wang, Z.-T., Wu, K., He, X., Dong, Q., & Yu, J. (2022) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-022-04614-6 · Cited by 58
Self-citationRole of primary aging hallmarks in Alzheimer´s disease
Zhao, J., & Huai, J. (2023) · Theranostics · doi:10.7150/thno.79535 · Cited by 51
“H3K4me3, associated with memory formation [272], is also elevated in the AD PFC and superior and medial temporal gyrus but is downregulated in the AD entorhinal cortex and hippocampus (Table 1) [169, 273-275].”
BackgroundSmall molecule modulators of chromatin remodeling: from neurodevelopment to neurodegeneration
Jiang, D., Li, T., Guo, C., Tang, T.-S., & Liu, H. (2023) · Cell & Bioscience · doi:10.1186/s13578-023-00953-4 · Cited by 54
Systemic aging and aging‐related diseases
Li, Q., Xiao, N., Zhang, H., Liang, G., Lin, Y., Qian, Z., Yang, X. Y., Yang, J., Fu, Y., Zhang, C., et al. (2025) · The FASEB Journal · doi:10.1096/fj.202402479rrr · Cited by 59
“26 Histone acetylation and deacetylation are catalyzed by HATs and HDACs, respectively.”
Pace, M., Giorgi, C., Lombardozzi, G., Cimini, A., Castelli, V., & d’Angelo, M. (2025) · Biomolecules · doi:10.3390/biom15081115 · Cited by 40
“Treatment with an inhibitor targeting H3K4 methyltransferases has been shown to restore functional activity in this brain region [97].”
WIN site inhibition disrupts a subset of WDR5 function
Siladi, A. J., Wang, J., Florian, A. C., Thomas, L. R., Creighton, J. H., Matlock, B. K., Flaherty, D. K., Lorey, S. L., Howard, G. C., Fesik, S. W., et al. (2022) · Scientific Reports · doi:10.1038/s41598-022-05947-9 · Cited by 37
Ma, K., Taylor, C., Williamson, M., Newton, S. S., & Qin, L. (2023) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2023.1182472 · Cited by 37
“The NOR test was used to assess object recognition memory (27, 28).”
MethodPatel, P. J., Ren, Y., & Yan, Z. (2023) · Neurobiology of Disease · doi:10.1016/j.nbd.2023.106192 · Cited by 36
Self-citationAlzheimer’s Disease-Related Epigenetic Changes: Novel Therapeutic Targets
Paniri, A., Hosseini, M. M., & Akhavan‐Niaki, H. (2023) · Molecular Neurobiology · doi:10.1007/s12035-023-03626-y · Cited by 36
“Inhibiting these methyltransferases with WDR5-0103 resulted in significant recovery of synaptic function and memory-related behaviors in AD mice [314].”
H3K4 Methylation in Aging and Metabolism
Hsu, C.-L., Lo, Y., & Kao, C.-F. (2021) · Epigenomes · doi:10.3390/epigenomes5020014 · Cited by 37
“In the AD mice, H3K4me3 and its catalyzing enzymes are significantly increased in the prefrontal cortex (PFC), a key brain region impaired in AD, and treating AD mice with a specific inhibitor of H3K4 KMTs results in substantial recovery of PFC functions [117].”
BackgroundEpigenetic treatment of behavioral and physiological deficits in a tauopathy mouse model
Wang, W., Cao, Q., Tan, T., Yang, F., Williams, J. B., & Yan, Z. (2021) · Aging Cell · doi:10.1111/acel.13456 · Cited by 33
“The spatial memory index (T1/T2) was calculated as previously described (Cao et al., 2020; Wang et al., 2018).”
MethodSelf-citationWilliams, J. B., Cao, Q., Wang, W., Lee, Y., Qin, L., Zhong, P., Ren, Y., Ma, K., & Yan, Z. (2023) · Nature Communications · doi:10.1038/s41467-022-35749-6 · Cited by 37
Self-citationA convergent mechanism of high risk factors ADNP and POGZ in neurodevelopmental disorders
Conrow‐Graham, M., Williams, J. B., Martin, J. A., Zhong, P., Cao, Q., Rein, B. A., & Yan, Z. (2022) · Brain · doi:10.1093/brain/awac152 · Cited by 29
Self-citationChemical biology and pharmacology of histone lysine methylation inhibitors
Barghout, S. H., Machado, R. A. C., & Baršytė-Lovejoy, D. (2022) · Biochimica et Biophysica Acta (BBA) - Gene Regulatory Mechanisms · doi:10.1016/j.bbagrm.2022.194840 · Cited by 34
Qin, Y., Yang, P. C., He, W., Li, D., Zeng, L., Li, J., Zhou, T., Peng, J., Cao, L., & Huang, W. G. (2024) · Clinical Epigenetics · doi:10.1186/s13148-024-01650-w · Cited by 26
“Elevated levels of H3K4me3 in the prefrontal cortex (PFC) and hippocampus are associated with the formation of long-term memory and the amelioration of memory deficits [27–30].”
BackgroundFirdaus, Z., & Li, X. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms252111658 · Cited by 26
“Among the genes upregulated in the prefrontal cortex of AD mice, many showed increased H3K4me3 enrichment in their promoters, which was reversed by treatment with WDR5-0103 [170].”
BackgroundInfluentialInsights into the Role of Histone Methylation in Brain Aging and Potential Therapeutic Interventions
Vitorakis, N., & Piperi, C. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms242417339 · Cited by 25
“Of note, the impairment of synaptic function and memory-related behavior associated with these changes was recovered upon selective inhibition of the respective histone methyltransferases mediating this mark [48].”
BackgroundWang, P., Wang, G., Li, H., Yuan, Y., Chen, H., Wang, S., Sun, Z., Meng, F., Li, Y., Yang, F., et al. (2024) · 癌症:英文版 · doi:10.1002/cac2.12633 · Cited by 23
Self-citationZhong, P., Cao, Q., & Yan, Z. (2022) · Cerebral Cortex · doi:10.1093/cercor/bhac036 · Cited by 23
“P301S Tau mice reconstitute a variety of AD-related phenotypes, including tau filament abnormality, synapse loss, synaptic dysfunction, microglial activation, cognitive behavioral deficits, and neurodegeneration (Allen et al. 2002; Yoshiyama et al. 2007; Takeuchi et al. 2011; Onishi et al. 2014; Cao et al. 2020; Wang…”
Self-citationOleson, B. J., Bhattrai, J., Zalubas, S. L., Kravchenko, T. R., Ji, Y., Jiang, E. L., Lu, C. C., Madden, C., Coffman, J. G., Bazopoulou, D., et al. (2023) · Nature Aging · doi:10.1038/s43587-023-00537-4 · Cited by 23
“Recent studies in mouse models of Alzheimer’s disease revealed that the pharmacological inhibition of the mammalian COMPASS complex substantially improved memory deficits in mouse models of Alzheimer’s disease 18 .”
Epigenetic regulation of synaptic disorder in Alzheimer’s disease
Chen, Z., Wu, M., Lai, Q., Zhou, W., Wen, X., & Yin, X. (2022) · Frontiers in Neuroscience · doi:10.3389/fnins.2022.888014 · Cited by 24
“Subsequently, introducing a specific Sgk1 inhibitor into mice reduced excessive phosphorylated tau proteins, restored the prefrontal cortex and glutamate synaptic function, and improved the memory defects in AD mice (Cao et al., 2020).”
BackgroundSGK1 drives hippocampal demyelination and diabetes-associated cognitive dysfunction in mice
Jiang, Z., Liu, B., Lu, T., Liu, X., Lv, R., Yuan, K., Zhu, M., Wang, X., Li, S., Xu, S., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-56854-2 · Cited by 24
“SGK1 was well acknowledged to play a pivotal role in maintaining cellular physiological activities, and the elevated SGK1 expression was associated with a variety of diseases, such as diabetes 47 , hypertension 52 , neurodegenerative diseases 48 and cancers 53 .”
AMPA receptors in Alzheimer disease: Pathological changes and potential therapeutic targets
Ning, L., Shen, R., Xie, B., Jiang, Y., Geng, X., & Dong, W. (2024) · Journal of Neuropathology & Experimental Neurology · doi:10.1093/jnen/nlae093 · Cited by 20
Zhang, X., Liu, Y., Huang, M., Gunewardena, S., Haeri, M., Swerdlow, R. H., & Wang, N. (2023) · Journal of Alzheimer s Disease · doi:10.3233/jad-230316 · Cited by 18
“inhibiting H3K4-specific methyltransferase amelio648 rates glutamatergic synaptic function and improves 649 memory-related behavior in AD mouse models 650 [53, 54].”
BackgroundWD Repeat Domain 5 Inhibitors for Cancer Therapy: Not What You Think
Weissmiller, A. M., Fesik, S. W., & Tansey, W. P. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13010274 · Cited by 19
“…of non-cancer applications have also been proposed, including improved in vitro fertilization in cattle [65], as well as treating aliments such as chronic kidney disease [66], neuropathic allodynia [67], Alzheimer’s [68], acute kidney injury [69], cardiac fibrosis [70], and atherosclerosis [71].”
BackgroundRani, N., Sahu, M., Ambasta, R. K., & Kumar, P. (2023) · Ageing Research Reviews · doi:10.1016/j.arr.2023.102174 · Cited by 18
The interplay between histone modifications and nuclear lamina in genome regulation
Sun, C., Zhao, Y., Guo, L., Qiu, J., & Peng, Q. (2024) · Journal of genetics and genomics/Journal of Genetics and Genomics · doi:10.1016/j.jgg.2024.10.005 · Cited by 18
Wang, W., Tan, T., Cao, Q., Zhang, F., Rein, B. A., Duan, W., & Yan, Z. (2022) · The International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyac048 · Cited by 17
“While we focused the measurement of cellular changes in PFC because of the key role of this brain region in regulating social and cognitive behaviors measured here (Duffney et al., 2015; Qin et al., 2018; Zheng et al., 2019; Cao et al., 2020; Rapanelli et al., 2021; Wang et al., 2021), the data from systemic administr…”
BackgroundMethodInfluentialSelf-citationFisher, R. M. A., & Torrente, M. P. (2024) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2024.1456052 · Cited by 20
Wan, L., Zhong, P., Li, P. S., Ren, Y., Wang, W., Yu, M., Feng, H. Y., & Yan, Z. (2025) · Neurobiology of Disease · doi:10.1016/j.nbd.2025.106826 · Cited by 14
“The PS19 mouse line harboring the T34 isoform of microtubule-associated protein tau encoding the human P301S mutation (Yoshiyama et al., 2007) was maintained as we previously described (Cao et al., 2020; Wang et al., 2021; Williams et al., 2023).”
InfluentialSelf-citationNanoparticles and Their Impact on Epigenetic Mechanisms: Insights and Implications
Hoseini, Z. S., Rezaee, Z., Derakhshani, A., Zhang, S., Tehrani, S., Taleb, M., & Ghanbari, H. (2025) · Advanced Therapeutics · doi:10.1002/adtp.202500006 · Cited by 16
Cao, Q., Kumar, M., Frazier, A., Williams, J. B., Zhao, S., & Yan, Z. (2023) · Aging · doi:10.18632/aging.205057 · Cited by 13
Self-citationGenetic and Epigenetic Interactions Involved in Senescence of Stem Cells
Iordache, F., Ionescu, A., & Alexandru, D. M. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25179708 · Cited by 14
“Treatment with different inhibitors of H3K4 histone methyltransferase boosts the recovery of prefrontal cortex function of mice [92].”
BackgroundHistone modifications: Key players in Alzheimer's disease
Li, K., Qiu, X., Yang, Q., & Wang, Z. (2025) · Mechanisms of Ageing and Development · doi:10.1016/j.mad.2025.112102 · Cited by 12
Self-citationXu, G., Yuan, M., He, H., Jin, Y., Li, X., Yan, H., Liu, G., Wu, Z., Zhang, X., Chen, Y., et al. (2025) · Molecular Psychiatry · doi:10.1038/s41380-025-03344-y · Cited by 17
The Future of Epigenetics: Emerging Technologies and Clinical Applications
Iyer, K. A., Tenchov, R., Sasso, J. M., Thite, T., Deng, Y., & Zhou, Q. A. (2026) · ACS Pharmacology & Translational Science · doi:10.1021/acsptsci.5c00729 · Cited by 15
Yu, W., Xu, J., Qiao, H., Liu, D., Sun, Y., Yan, R., Zhang, C., Yu, N., Song, Y., Ling, M., et al. (2024) · Journal of Proteomics · doi:10.1016/j.jprot.2024.105335 · Cited by 12
YaPing, Z., Ai, W., Zheng, J., Hu, X., & Zhang, L. (2024) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2024.1332845 · Cited by 12
“…including DNA methylation and hydroxy methylation, histone modifications, and regulation of non-coding RNAs (ncRNAs) were closely linked to AD and helpful for the treatment of AD (Wang et al., 2020; Wu and Kuo, 2020; Xiao et al., 2020; Lauretti et al., 2021; Nikolac Perkovic et al., 2021).”
BackgroundSaleem, K., Xiao, Z., Zhu, B., Ren, Y., Yan, Z., & Feng, J. (2026) · Molecular Psychiatry · doi:10.1038/s41380-025-03225-4 · Cited by 10
“The increased expression of SGK1 and its ability to phosphorylate Tau [17] led us to examine whether the increased phosphorylation of Tau is connected to SGK1.”
InfluentialSelf-citationLysine-specific methyltransferase Set7/9 in stemness, differentiation, and development
Daks, A. A., Parfenyev, S. E., Shuvalov, O. Y., Fedorova, O., Nazarov, A., Melino, G., & Barlev, N. A. (2024) · Biology Direct · doi:10.1186/s13062-024-00484-z · Cited by 10
“In accordance, targeting H3K4 methylation with small molecule inhibitors resulted in the recovery of prefrontal cortex synaptic function and memory in AD mouse models and can be considered a promising strategy for AD treatment [149].”
BackgroundThe role of SGK1 in neurologic diseases: A friend or foe?
Chen, X., Kang, H., & Xiao, Y. (2024) · IBRO Neuroscience Reports · doi:10.1016/j.ibneur.2024.12.003 · Cited by 10
Kim, Y. A., Mellén, M., Kızıl, Ç., & Santa‐María, I. (2023) · British Journal of Pharmacology · doi:10.1111/bph.16280 · Cited by 9
“…and cerebrovascular dysfunction (Klein et al., 2019) Histone methylation Histone mark H3K4me3 at transcription start sites Tauopathy pathogenesis (Cao et al., 2020) Histone lactylation Histone mark H4K12la enriched at promoters of glycolytic genes such as PKM2, Ldha and Hif-1alpha Tauopathy…”
BackgroundLiu, M., Lian, B., Lan, Z., Sun, H., Zhao, Y., Sun, T., Meng, Z., Zhao, C., & Zhang, J. (2022) · Neurochemical Research · doi:10.1007/s11064-022-03690-1 · Cited by 8
Manganese induces neuronal apoptosis by activating mTOR signaling pathway in vitro and in vivo
Cen, Y., Yang, J., Su, L., Wang, F., Zhu, D., Zhao, L., & Li, Y. (2024) · Food and Chemical Toxicology · doi:10.1016/j.fct.2024.114508 · Cited by 8
Tiwari, P., Dwivedi, R., Kaushik, M., Tripathi, M., & Dada, R. (2025) · Journal of Molecular Neuroscience · doi:10.1007/s12031-025-02363-2 · Cited by 10
“WDR5 inhibitors, such as WDR5-42, target the WDR5 protein, which regulates chromatin remodeling and gene expression by interacting with histone methyltransferases (Pereira et al. 2024; Cao et al. 2020).”
Reappraisal of the Concept of Accelerated Aging in Neurodegeneration and Beyond
Statsenko, Y. A., Kuznetsov, N. V., Morozova, D., Liaonchyk, K., Simiyu, G. L., Smetanina, D., Kashapov, A., Meribout, S., Gorkom, K., Hamoudi, R., et al. (2023) · Cells · doi:10.3390/cells12202451 · Cited by 11
An epigenetic mechanism of social isolation stress in adolescent female mice
Li, P., & Yan, Z. (2023) · Neurobiology of Stress · doi:10.1016/j.ynstr.2023.100601 · Cited by 9
“…H3K9 methylation can regulate genes related to synaptic dysfunction (Benevento et al., 2016; Gupta-Agarwal et al., 2012; Maze et al., 2010; Wang et al., 2020; Zheng et al., 2019), so we also investigated the expression of genes related to glutamatergic synapses in PFC of SI females.”
InfluentialSelf-citationN-terminal acetylation of Set1-COMPASS fine-tunes H3K4 methylation patterns
Woo, H., Oh, J., Cho, Y., Oh, G. T., Kim, S., Dan, K., Han, D., Lee, J., & Kim, T. S. (2024) · Science Advances · doi:10.1126/sciadv.adl6280 · Cited by 11
Auta, J., Locci, A., Guidotti, A., Davis, J. M., & Dong, H. (2021) · Current Research in Neurobiology · doi:10.1016/j.crneur.2021.100025 · Cited by 9
“In a recent study, Cao, and colleagues (Cao et al., 2020) reported significant increases of H3K4me3 epigenetic mark in”
BackgroundWu, C., Hsieh, Y., Tseng, H.-Y., Huang, Y.-H., Li, Y., Hung, T., Wang, S.-P., & Wu, Y. (2022) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2022.113663 · Cited by 8
Bolouki, A., Rahimi, M., Azarpira, N., & Baghban, F. (2023) · Psychiatric Genetics · doi:10.1097/ypg.0000000000000340 · Cited by 8
“memory-related behaviors in AD mice (Cao et al., 2020; Solich et al., 2021).”
Histone demethylase PHF2 regulates inflammatory genes in Alzheimer’s disease
Yang, G., Ren, Y., Zhong, P., Patel, P., Chen, X.-Q., Wan, L., Lee, Y. H., Saleem, K., Feng, J., & Yan, Z. (2025) · Molecular Psychiatry · doi:10.1038/s41380-025-03181-z · Cited by 7
“Transgenic mice carrying fi ve familial AD mutations on human amyloid precursor protein (Swedish K670N/M671L Florida I716V and London V717I) and human presenilin1 (M146L and L286V) were maintained and genotyped as we previously reported [16 – 18].”
Self-citationSETD7 Dual Role in Disease and Opportunities for Therapeutic Intervention: Current Perspectives
Baboni, F., Tembo, K. M., Zhou, X., Li, Q., Dai, Y., Zhao, Y., Batoko, S., Lan, P., & Chen, Z. (2025) · Journal of Inflammation Research · doi:10.2147/jir.s534623 · Cited by 7
“37,122,123 The inhibition of SETD7 has also been shown to alleviate cognitive dysfunction via the suppression of NOD-like receptor protein 3 (NLRP3) inflammasome activation in isoflurane-induced aged mice.”
Epigenetic Inhibitors as Alzheimer’s Disease Therapeutic Agents
Yamashita, Y., Itoh, Y., Takada, Y., & Suzuki, T. (2024) · Chemical and Pharmaceutical Bulletin · doi:10.1248/cpb.c23-00027 · Cited by 7
Higher Intron Retention Levels in Female Alzheimer's Brains May Be Linked to Disease Prevalence
Choo, C., Leow, C., & Ong, C. (2025) · Aging Cell · doi:10.1111/acel.14457 · Cited by 9
“H3K4me3 and H3K27ac levels were elevated in AD brains (Cao et al. 2020; Nativio et al. 2020).”
Chai, G., Gong, J., Mao, Y.-M., Wu, J.-J., Bi, S.-G., Wang, F., Zhang, Y., Shen, M.-T., Lei, Z.-Y., Nie, Y., et al. (2024) · Molecular Neurobiology · doi:10.1007/s12035-024-03995-y · Cited by 8
“Recent pathological studies have highlighted reduced histone acetylation and elevated histone methylation’s critical roles in memory [15–17].”
Unraveling the complexity of the histone code: implications for gene regulation and disease
Malone, K. L., Singh, A. K., Lignos, J. M., Cook, E. D., Phillips, M., Boyle, B. W., Kressy, I. A., Vulikh, M., Lathrop, A. K., McKay, K. T., et al. (2026) · Genome biology · doi:10.1186/s13059-026-04011-3 · Cited by 7
“In AD patients increased levels of H3K4me3 are detected in affected brain regions, likely reflecting the hyperactivation of methyltransferases [283, 284].”
Zhou, Y., Jiang, L. H., Zhang, Y., Zhou, C., Yang, H., He, Q., Wang, Y., Xiao, Q., Huang, D., Luo, Y., et al. (2023) · Neuroscience Research · doi:10.1016/j.neures.2023.02.005 · Cited by 6
The Neuroepigenetic Landscape of Vertebrate and Invertebrate Models of Neurodegenerative Diseases
Sundaramoorthy, T. H., & Castanho, I. (2022) · Epigenetics Insights · doi:10.1177/25168657221135848 · Cited by 6
Lian, P., Cai, X., Wang, C., Zhai, H., Liu, P., Yang, X., Wu, Y., Ma, Z., Cao, X., & Xu, Y. K. (2024) · Heliyon · doi:10.1016/j.heliyon.2024.e33836 · Cited by 5
An Update on Neuroaging on Earth and in Spaceflight
Kuznetsov, N. V., Statsenko, Y. A., & Ljubisavljević, M. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26041738 · Cited by 7
“Research showed an increase in H3K4me3 promoter methylation in a CK-p25 tauopathy mouse model and the hippocampus of AD patients [164,165].”
Mishra, A., Satapathy, B. S., Sahu, P. K., Ghose, A., & Paidesetty, S. K. (2026) · ACS Omega · doi:10.1021/acsomega.6c00142 · Cited by 3
Mechanisms and interventions of epigenetic aging
Chu, Q., Li, Y., Wu, Z., Qu, J. T., & Liu, G. (2026) · Cell chemical biology · doi:10.1016/j.chembiol.2026.05.007 · Cited by 6
Madruga, E., Sanchez-Santos, C., Martínez, I., Ramírez, D., Gil, C., & Martínez, A. (2025) · Journal of Enzyme Inhibition and Medicinal Chemistry · doi:10.1080/14756366.2025.2546591 · Cited by 3
“Furthermore, SGK1 is also up-regulated in the prefrontal cortex of both animal models, as well as in post-mortem aD patients’ samples 16 . accordingly, treatment with sGK1 inhibitors may open new therapeutic avenues for this devastating neurodegenerative disease. however, until now, efforts in the…”
The impact of sex on memory during aging and Alzheimer's disease progression: Epigenetic mechanisms
Scheinman, S. B., & Dong, H. (2024) · Journal of Alzheimer s Disease · doi:10.1177/13872877241288709 · Cited by 3
“For example, levels of methyltransferases were elevated in the PFC of 5xFAD and P301 mice compared to wild type controls 122,124 indicating higher overall methylation activity.”
Patel, P. J., & Yan, Z. (2026) · Journal of Alzheimer s Disease · doi:10.1177/13872877251414887 · Cited by 3
Self-citationEpitranscriptomic regulation of cognitive development and decline
Wang, D. O. (2021) · Seminars in Cell and Developmental Biology · doi:10.1016/j.semcdb.2021.11.019 · Cited by 2
Epigenetics of Altered Circadian and Sleep Cycle Induced Effects on Aging and Longevity
Patel, S., Vijay, V., Kumar, A., & Chakravarty, S. (2023) · Healthy ageing and longevity · doi:10.1007/978-3-031-22468-3_17 · Cited by 2
Alzheimer’s Disease and Epigenetics
Örenay-Boyacıoğlu, S., Boyacıoğlu, O., & Döndü, A. (2024) · Springer eBooks · doi:10.1007/978-3-031-32035-4_172-1 · Cited by 2
Park, S., Liu, Y., Lim, S., Ryu, H., & Ahn, S. H. (2025) · iScience · doi:10.1016/j.isci.2025.112846 · Cited by 2
Epigenetics-based treatment strategies for Alzheimer’s disease
Cao, Q., Wang, W., & Yan, Z. (2022) · Aging · doi:10.18632/aging.204096 · Cited by 2
Self-citationZhong, P., Cao, Q., & Yan, Z. (2024) · Journal of Alzheimer s Disease · doi:10.3233/jad-231413 · Cited by 1
Self-citationMittal, Y., Kumar, P., Joshi, K., & Aran, K. R. (2025) · Inflammopharmacology · doi:10.1007/s10787-025-01777-z · Cited by 2
Alzheimer’s Disease and Epigenetics
Örenay-Boyacıoğlu, S., Boyacioglu, O., & Döndü, A. (2025) · Springer eBooks · doi:10.1007/978-3-031-73368-0_172 · Cited by 1
Yeasmin, A., & Torrente, M. P. (2025) · Biology · doi:10.3390/biology14111556 · Cited by 1
“Additionally, TAU-AD patient brains indicate increased levels of H3S10ph, agreeing with the notion of cell cycle reentry in AD along with mitotic machinery activation, although not necessarily linked to TAU [229,237–239].”
Epigenetic Changes in Alzheimer’s Disease and Interventions for Therapy
Xu, M., Xiong, L., Qin, Z., Yu, X., Chen, T., Zhang, X., Jin, M., Wang, L., Cai, L., Wei, Y., et al. (2026) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s576404 · Cited by 2
“14,39,40 An increase in H3K9me2 levels is associated with a decrease in the expression levels of the glutamate receptor subunits AMPAR and NMDAR, which are crucial for the normal function of neurons.”
Tripathi, A., Sharma, G., Pandey, V. K., Rustagi, S., Sharma, A. R., Jha, M., Debnath, A., Joy, J. G., Kim, J., & Jha, A. K. (2026) · GeroScience · doi:10.1007/s11357-026-02107-z · Cited by 1
Zhong, P., Shaker, T., Li, P., & Yan, Z. (2026) · The Journal of Physiology · doi:10.1113/jp289018 · Cited by 1
“One of the upregulated kinases that can lead to tau hyperphosphorylation in AD is SGK1 (Cao et al., 2020; Yang et al., 2006).”
InfluentialSelf-citationBrain Permeable SGK1 Inhibitors: A Promising Therapeutic Strategy for Neurodegenerative Diseases
Madruga, E. L., García‐Rubia, A., Sanchez-Nuñez, C., Martínez-González, L., Fernández‐Escamilla, A. M., Lastres‐Becker, I., Gil, C., & Martínez, A. (2026) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5c03050 · Cited by 1
RFWD2 Mitigates AD ‐Like Cognitive Impairments via the JNK – SGK1 Signaling Pathway in Mice
Ying, M., Qi, X., Wang, A., Zhong, G., Tong, W., Yu, D., Liu, G., & Guo, Y. (2026) · CNS Neuroscience & Therapeutics · doi:10.1002/cns.70860 · Cited by 1
“Their research emphasized the significance of epigenetic regulation and highlighted the key role of SGK1 in AD [26].”
Deng, S., Gao, S., Zhou, C., Lan, Z., Li, H., Chen, J., Xu, Y., Li, J., Liu, P., Zhang, S., et al. (2026) · CNS Neuroscience & Therapeutics · doi:10.1002/cns.71150 · Cited by 1
Early exposure to a systemic stressor confers protection later in life
Srinivasan, S. (2024) · Nature Aging · doi:10.1038/s43587-023-00553-4 · Cited by 1
Gorina, Y. V., Salmina, A. B., Chernyuk, D., Bolshakova, A. V., Balaban, P. M., Борисович, Б. И., & Власова, О. Л. (2022) · Neuroscience and Behavioral Physiology · doi:10.1007/s11055-022-01301-8
“For example, recent studies [Cao et al., 2020] demonstrated the positive effects of modulators of epigenetic mechanisms of regulation of gene expression (H3K4-specifi c methyltransferase inhibitor) in 5xFAD mice, which is pathogenetically justifi ed: neurons in the prefrontal cortex of these…”
ResultGene-expression control in early and late-onset dementia
Zhou, J. (2022) · eDiss (Georg-August-Universität Göttingen) · doi:10.53846/goediss-9465
Liu, L., Qian, L., Yang, H., Ye, Q., Xu, Z., Liu, Y., Wang, Z., Wu, W., & Liu, X. (2023) · Research Square · doi:10.21203/rs.3.rs-3206277/v1
Self-citationEpigenetics and cognitive disorders—translational aspects
Coppedè, F. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-18516-8.00016-8
Recent Advances in the Study of Biomarkers of Aging
肖, 夤. (2025) · Advances in Clinical Medicine · doi:10.12677/acm.2025.153869
Inhibition of histone lysine demethylase restores learning and memory in aged micePreprint
Bhatt, S. R., MacBean, L. F., Kramár, E. A., Pérez‐Sisqués, L., Smethurst, P., Robb, J. L., Jindal, N., Fetterly, T. L., Graham, A., Wood, M. A., et al. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2025.12.22.695858 · Cited by 3
“HT-22 cells were cultured for 24h in the presence of WDR5-0103 [40] GSK-LSD1 [41] or AR-42 [42] in 10-point dose response curves, followed by fixation and H3K4me3 immunostaining (Fig.”
Metadata
- Authors
- Cao, Q., Wang, W., Williams, J. B., Yang, F., Wang, Z.-J., & Yan, Z.
- Affiliations
- University at Buffalo, State University of New York (US)
- Department of Physiology and Biophysics, School of Medicine and Biomedical Sciences, State University of New York at Buffalo, Buffalo, NY, USA.
- Corresponding author
- Yan, Zhen
- Venue
- Science Advances
- Published
- 2020-12-11
- Volume
- 6
- Issue
- 50
- ISSN
- 2375-2548 (ISSN-L)
- PMC
- PMC7725456
- OpenAlex
- W3111509032
- Cited by
- 108
- References
- 73
- Citations by year
- 2026: 19 · 2025: 20 · 2024: 23 · 2023: 21 · 2022: 17 · 2021: 8
- FWCI
- 6.92
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Science Advances (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- Funders
- National Institutes of Health (AG064656, AG056060, AG067597)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuroscience and Neuropharmacology Research
- Keywords
- histone H3 lysine 4 trimethylation, Alzheimer's disease, SGK1, SGK1 inhibitor, tau hyperphosphorylation, prefrontal cortex, memory impairment, epigenetic therapy, cognitive impairment
- MeSH terms
- Alzheimer Disease, Animals, Cognition, Disease Models, Animal, Histones, Humans, tau Proteins, Epigenesis, Genetic, Intracellular Signaling Peptides and Proteins, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.